�the kind of review being proposed does not, at least initially, appear to bring anything new or needed to is already a robust system of oversight,� mogulof said in the statement.
.
.
.
.
china's plans to import indian drugs fail to enthuse indian pharmaceutical firms
.
may 15, 2018
.
.
.
.